AllSight
Companies · SPRY · Pharmaceutical Preparations · Earnings · Aug 13, 2026

neffy is growing—but ARS just admitted the launch was overspending

In linenew
$33.7M revenue vs ~$32.0M consensus; EPS -$0.63 vs ~-$0.50 consensus
ARS Pharmaceuticals, Inc. (SPRY) — what happened, in plain English, and what it means versus what the market expected.

The next major valuation test is clinical, not another routine quarter. Interim Phase 2b data for ARS-2 in chronic spontaneous urticaria is now expected in Q1 2027. The program could expand the platform into an area with no FDA-approved on-demand treatment for acute flares, but the filing provides no efficacy result yet; for now, it is an option value rather than delivered evidence. (Expanding the Intranasal Epinephrine Platform)

Read the original 8-K on SEC EDGAR ↗
All SPRY filings, decoded →
Related companies in Pharmaceutical Preparations
ONCELANCMPSUTHRPRGOETONQTTBLLY
Latest across the market
NTSTNETSTREIT debt amendment formalizes investment-grade pricing and widens leverage cushionFLOCFlowco acquisition adds Canadian rod lift but increases debt-funded execution riskCTRECareTrust acquisition adds 45 UK care homes, but SHOP payoff is years awayADCAgree Realty share-count filing adds routine dilution detail, not new business newsACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact